Welcome to our dedicated page for ARS Pharms news (Ticker: SPRY), a resource for investors and traders seeking the latest updates and insights on ARS Pharms stock.
Stock Titan’s news page for ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) aggregates company-specific updates for investors and followers of this commercial-stage biopharmaceutical company. ARS Pharma describes its focus as empowering at-risk patients and caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, primarily through its epinephrine nasal spray product, neffy®.
News coverage for SPRY commonly includes announcements about regulatory approvals and geographic expansion of neffy and EURneffy®. Recent press releases highlight approvals for neffy in markets such as Japan and China, as well as launches and approvals in Europe and the U.K. These items provide insight into how ARS Pharma is extending access to its needle-free epinephrine nasal spray through partnerships with companies including ALK, Alfresa Holdings, and Pediatrix Therapeutics.
Investors can also expect commercial and financial updates, such as quarterly financial results, commentary on U.S. commercialization progress, and details on direct-to-consumer campaigns and programs like “Get neffy on Us” and neffyInSchools. These disclosures often describe prescriber adoption, marketing initiatives, and real-world evidence efforts related to neffy’s use in community and clinical settings.
Another key category of SPRY news involves scientific and medical conference activity. ARS Pharma regularly reports on late-breaking oral presentations, poster sessions, and case reports at meetings such as the American College of Allergy, Asthma and Immunology Annual Scientific Meeting, focusing on real-world data, patient experience, dosing rationale, safety, and product stability for intranasal epinephrine.
Additional items may include intellectual property developments, such as decisions from the European Patent Office or the U.S. Patent and Trademark Office, as well as legal and competitive updates like Paragraph IV certification notices regarding potential generic versions of neffy. By following this news feed, readers can monitor how ARS Pharma communicates its regulatory, commercial, scientific, and legal milestones related to neffy and its intranasal epinephrine program.
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Monday, November 10, 2025 at 5:30 a.m. PT / 8:30 a.m. ET to discuss third quarter 2025 financial results and business highlights. Dial-in details are available by registering for the event.
Investors can access the live webcast and slides on the company’s Investors & Media > Events & Presentations page. A replay of the webcast will be available for 30 days after the event.
ARS Pharma (Nasdaq: SPRY) will present one late-breaking oral and six poster presentations on neffy® (epinephrine nasal spray) at the ACAAI Annual Scientific Meeting, Nov 6-10, 2025 in Orlando.
Presentations include a late-breaking oral update reporting that about 9 of 10 patients with anaphylaxis were effectively treated with a single dose of neffy, five case reports of in-clinic use, and posters on patient experience, dosing technique, safety, stability, and second-dose rationale.
Attendees can visit booth #400 and multiple onsite sessions for more details.
ARS Pharmaceuticals (NASDAQ: SPRY) announced the European Patent Office Opposition Division upheld all claims of EP 3678649, a patent covering nasal spray epinephrine formulations including alkyl-glycoside excipients such as Intravail®. The patent is validated in over 30 European countries and ARS states its global intellectual property for neffy provides coverage through at least 2039. Earlier in 2025 the USPTO also upheld key claims of U.S. Patent No. 10,682,414 after an IPR challenge and appeal, giving ARS two different patents with differing claim scope sustained in separate jurisdictions.
Company commentary framed the rulings as reinforcing the strength of its worldwide patent estate that covers intranasal epinephrine.
ARS Pharmaceuticals (NASDAQ: SPRY) has secured a substantial $250 million senior secured term loan facility from RA Capital Management and OMERS Life Sciences. The company has initially borrowed $100 million to accelerate the commercialization of neffy®, their needle-free epinephrine treatment for allergic reactions.
The loan facility includes favorable terms with an interest rate of SOFR plus 5.5% and interest-only payments until September 2030. The company has access to additional tranches: $25 million available within 6-12 months, another $25 million subject to achieving $100 million in U.S. revenue, and an uncommitted $100 million incremental term loan.
Market response to neffy® has been strong, with 93% of patients surveyed being "very likely to consider" the treatment and the prescriber base nearly doubling in four months. The company expects the funding to support operations through cash-flow breakeven while targeting the $2 billion annual U.S. epinephrine market.
ARS Pharmaceuticals (NASDAQ:SPRY) has received Japanese regulatory approval for neffy®, the first needle-free epinephrine nasal spray for emergency treatment of allergic reactions (anaphylaxis). The approval covers both 1mg and 2mg doses for adults and children weighing over 15kg.
Through a partnership with Alfresa Holdings, neffy is expected to launch in Japan by Q4 2025. The approval triggers a $2 million milestone payment to ARS Pharma. This breakthrough addresses a significant market need, as approximately 900,000 Japanese individuals are affected by food allergies, yet only 14% of anaphylaxis patients reported having an epinephrine auto-injector prescription.
The product features a 24-month shelf life and is already commercially available in the US and parts of Europe, with additional approvals expected in Canada, Australia, New Zealand, and China by early 2026.
ARS Pharmaceuticals (NASDAQ:SPRY) has reported compelling real-world evidence for its neffy® (epinephrine nasal spray) in treating anaphylaxis. The study, accepted for publication in the Annals of Allergy, Asthma and Immunology, demonstrated that 89.2% of 545 patients experiencing anaphylaxis during oral food challenges and allergen immunotherapy were successfully treated with a single dose of neffy.
This success rate closely mirrors the 88.9% efficacy rate historically reported for traditional epinephrine injections, suggesting clinical interchangeability between the two delivery methods. The findings build upon previous clinical evidence, including a Phase 3 study, and represent the first large-scale analysis of neffy's treatment outcomes in routine clinical practice.
ARS Pharmaceuticals (NASDAQ:SPRY), a biopharmaceutical company focused on anaphylaxis prevention, announced its participation in two upcoming investor conferences. The company's leadership will present at the Cantor Global Healthcare Conference on September 3, 2025, at 3:55 p.m. ET in New York, and the Stifel Immunology and Inflammation Summit on September 15, 2025, at 12:00 p.m. ET virtually.
Co-Founder, President and CEO Richard Lowenthal and Chief Commercial Officer Eric Karas will represent the company. Live webcasts will be available on the company's website, with replays accessible for 30 days after each event.
ARS Pharmaceuticals (NASDAQ: SPRY) reported strong Q2 2025 financial results, highlighting significant growth for neffy®, their needle-free epinephrine nasal spray. The company achieved $15.7 million in total revenue, including $12.8 million from U.S. neffy sales. Key commercial milestones include 93% commercial coverage and a 180% increase in prescription volumes from Q1 to Q2 2025.
The company has expanded globally with EURneffy® approval in the UK and launch in Germany. Financial position remains strong with $240.1 million in cash and investments, supporting operations for at least three years despite a net loss of $44.9 million for the quarter. The company has initiated a Phase 2b trial for urticaria and expects additional regulatory approvals in Canada, Japan, Australia, and China by 2026.
ARS Pharmaceuticals (Nasdaq: SPRY), a biopharmaceutical company focused on anaphylaxis prevention, will host a conference call and webcast to discuss its Q2 2025 financial results on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET.
Participants can register for the event to receive dial-in information. The webcast and presentation slides will be accessible through the Events & Presentations page on the company's website, with a replay available for 30 days after the event.
ARS Pharmaceuticals (NASDAQ:SPRY) has achieved a significant milestone as the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved EURneffy, the first needle-free adrenaline nasal spray for emergency treatment of allergic reactions. The approval covers adults and children weighing over 30 kg.
The company's partnership with ALK-Abelló A/S includes a $145 million upfront payment and potential additional payments of up to $320 million in milestones, plus tiered double-digit royalties. The UK represents the largest market outside the US for adrenaline auto-injector sales. EURneffy's launch is expected in late Q3 2025.
The product offers advantages including temperature stability up to 50°C and longer shelf life compared to auto-injectors. Additional regulatory approvals are anticipated in Canada, Japan, and Australia by end of 2025, with China following in 2026.